For CD8+ cell depletion, an orthotopic NAFLD-HCC model was constructed using Hepa1-6-sgnc-lucifrase cells or Hepa1-6-sgMETTL3-luciferase cells. Anti-CD8α antibody (clone 2.43; BioXCell) was intraperitoneal injected on Day -1,2,5,8,11 (200ug in 100 μL PBS per mouse for the first time, and 100μg/mice for the following doses at the indicated time). For the control group, the same amount of isotype-matched rat IgG2α antibody were injected at the same time.
Anti cd8α antibody clone 2.43
Manufactured by BioXCell
Sourced in United States
The Anti-CD8α antibody (clone 2.43) is a mouse monoclonal antibody that specifically binds to the CD8α subunit of the CD8 protein complex. CD8α is expressed on the surface of certain T lymphocytes and is involved in the recognition of antigens presented by MHC class I molecules. This antibody can be used to identify and study CD8+ T cells.
Automatically generated - may contain errors
4 protocols using anti cd8α antibody clone 2.43
1
Orthotopic NAFLD-HCC Model with CD8+ Cell Depletion
2
T Cell Depletion for Influenza Virus Challenge
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
T cell depletion was performed according to previously established protocols (36 (link), 52 (link)). Briefly, vaccinated mice were injected intraperitoneally (i.p.) with 100 μg of anti-CD8α antibody (clone 2.43) or anti-CD4 antibody (clone GK1.5) or with both anti-CD8 and anti-CD4 or isotype control (IgG2b) antibodies (Bio X Cell) at days −4, −2, 0, and 3. Depletion of T cells was confirmed at day −1 to ensure greater than 98% depletion compared with the results seen with the isotype control. Mice were challenged with H7N9 virus (10 MLD50) at day 0 and monitored for 14 days.
3
CD8+ T-cell Depletion in Anti-tumor Efficacy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
MC38 subcutaneous tumor-bearing mice were intraperitoneally administered with either PBS or anti-CD8α antibody (clone 2.43, 200 µg/injection, BioXCell, Lebanon, NH, USA) on days 1, 3, 6, 9, and 12. To determine the role of CD8+ T cells in the anti-tumor efficacy of Lm-LLO-ISG15, three groups of mice were included: Group 1 (Mock) received PBS + PBS, group 2 (Vaccinated) received Lm-LLO-ISG15 + PBS, and group 3 (CD8+ T-cell depletion) received Lm-LLO-ISG15 + anti-CD8α. The mice were monitored for tumor growth kinetics and survival.
4
Depletion of Immune Cells in LCMV Infection
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In order to deplete CD169+ macrophages at day 5 p.i., diphtheria toxin (DT; Sigma-Aldrich) was i.p. injected into CD169DTR transgenic mice (30 μg/kg) at day 3 post-acute infection. Physiological serum was used as a control vehicle. CD8 T cell depletion in acute and chronic LCMV infection was performed by i.p. administration of 200 μg of anti-CD8α antibody (clone 2.43; Bio X Cell) respectively at days -1 and 2 p.i. and at days 7 and 10 p.i. For depletion of NK cells, chronic LCMV-infected mice were i.p. injected with 75 μg of anti-NK1.1 antibody (clone PK136; Bio X Cell) at days -3 and -2 p.i.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!